Zimura in Subjects With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Part 1: Approximately 66 subjects will be randomized in a 1:1:1 ratio to the following dose
groups:

- Zimura Dose Administration 1

- Zimura Dose Administration 2

- Sham Administration 1

Part 2: Approximately 135 subjects will be randomized in a 1:2:2 ratio to the following dose
groups:

- Zimura Dose Administration 3

- Zimura Dose Administration 4

- Sham Administration 2

Subjects will receive monthly intravitreal injections of Zimura or Sham for 18 months.

Inclusion Criteria:

- Subjects of either gender aged ≥ 50 years

- Diagnosis of Non-foveal GA secondary to dry AMD

Exclusion Criteria:

- Evidence of Choroidal Neovascularization (CNV)

- GA secondary to any condition other than AMD

- Any prior treatment for AMD or any prior intravitreal treatment for any indication in
either eye, except oral supplements of vitamins and minerals

- Any intraocular surgery or thermal laser within three (3) months of trial entry

- Any prior thermal laser in the macular region, regardless of indication

- Any ocular or periocular infection in the twelve (12) weeks

- Previous therapeutic radiation in the region of the study eye

- Any sign of diabetic retinopathy in either eye